インプラント透析装置開発のためのラット長期in vivo実験プロトコルの開発

抄録

Currently, the number of patients with severe chronic kidney disease in Japan exceeds 320,000. Most of these patients goes to the hospital three times a week and must receive about 4 hours of dialysis treatment every time. Therefore, we aim to develop an implantable dialysis system that uses a MEMS technology to make the dialysis system smaller and simpler. In this process, long-term in vivo experiments with small animals are advantageous, but at that time, blood coagulation management becomes a problem. Therefore, in this paper, the appropriate dose of heparin was quantitatively evaluated from the viewpoint of APTT by in vivo experiments using rats. It was confirmed that the half-life of heparin in the rat body was about 15 minutes. Also, the patency of microfluidic channel of devices were confirmed up to 72 h by administering heparin in device connection experiment using rats in anesthesia arousal state.